Drug Trial Radar · NCT05329649
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
13
Actual
Start
May 2, 2022
Primary completion
Jun 6, 2027
Study completion Jun 6, 2027
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- Collaborators
- CRISPR Therapeutics
- First posted
- Apr 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
Conditions
- Sickle Cell Disease
- Hydroxyurea Failure
- Hydroxyurea Intolerance
- Hemoglobinopathies
- Hematological Diseases
Interventions
CTX001Biological
Administered by intravenous infusion following myeloablative conditioning with busulfan.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants who do not Have any Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months (VF12)Time frame: Up to 24 Months After CTX001 Infusion
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
Levine Children's Hospital - Hematology
Charlotte, North Carolina
The Children's Hospital of Philadelphia - Hematology
Philadelphia, Pennsylvania
St. Jude Children's Research Hospital
Memphis, Tennessee
TriStar Medical Group Children's Specialists - Pediatric Oncology
Nashville, Tennessee
University Hospital Duesseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology
Düsseldorf, Germany
IRCSS Ospedale Pediatrico Bambino Gesu - Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica
Rome, Italy
St.Mary's Hospital - Haematology Dept
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.